EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model

Chenwei Wang, Jiewen Chen, Jingyao Li, Zhihong Xu, Lihong Huang, Qian Zhao, Lei Chen, Xiaolong Liang, Hai Hu, Gang Li, Chengjie Xiong, Bin Wu und 6 weitere

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci172092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Chenwei Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Medical University-Guangzhou Institute of Biomedicine and Health (GMU-GIBH) Joint School of Life Sciences and Guangdong-Hong Kong-Macau Joi…. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangzhou Basic and Applied Basic Research Foundation, Henan Provincial Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive transfer of T cell receptor–engineered T cells (TCR-T) is a promising strategy for immunotherapy against solid tumors. However, the potential of CD4 + T cells in mediating tumor regression has been neglected. Nasopharyngeal cancer is consistently associated with EBV. Here, to evaluate the therapeutic potential of CD4 TCR-T in nasopharyngeal cancer, we screened for CD4 TCRs recognizing EBV nuclear antigen 1 (EBNA1) presented by HLA-DP5. Using mass spectrometry, we identified EBNA1 567–581 , a peptide naturally processed and presented by HLA-DP5. We isolated TCR135, a CD4 TCR with high functional avidity, that can function in both CD4 + and CD8 + T cells and recognizes HLA-DP5–restricted EBNA1 567–581 . TCR135-transduced T cells functioned in two ways: directly killing HLA-DP5 + EBNA1 + tumor cells after recognizing EBNA1 presented by tumor cells and indirectly killing HLA-DP5–negative tumor cells after recognizing EBNA1 presented by antigen-presenting cells. TCR135-transduced T cells preferentially infiltrated into the tumor microenvironment and significantly inhibited tumor growth in xenograft nasopharyngeal tumor models. Additionally, we found that 62% of nasopharyngeal cancer patients showed 50%–100% expression of HLA-DP on tumor cells, indicating that nasopharyngeal cancer is well suited for CD4 TCR-T therapy. These findings suggest that TCR135 may provide a new strategy for EBV-related nasopharyngeal cancer immunotherapy in HLA-DP5 + patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal NeoplasmsMiceAnimalsHumansHerpesvirus 4, HumanReceptors, Antigen, T-CellCD4-Positive T-LymphocytesImmunotherapyImmunotherapy, AdoptiveTumor Microenvironment

Stichwörter der Autor:innen

Cancer immunotherapyImmunologyT cell receptor

Substanzen

Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Guangzhou Medical University-Guangzhou Institute of Biomedicine and Health (GMU-GIBH) Joint School of Life Sciences and Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical…
  • State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.
  • Laboratory for Synthetic Chemistry and Chemical Biology Limited, Hong Kong, China.
  • Department of Pathology, Air Force Hospital of Southern Theater Command, Guangzhou, Guangdong, China.
  • Department of Otolaryngology-Head and Neck Surgery, Huiqiao Medicine Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Laboratory for Excellence in Systems Biomedicine of Pediatric Oncology, Department of Pediatric Hematology and Oncology, Children's Hospital of Chongqing Medical University, Chongqing, China.

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Basic and Applied Basic Research Foundation
  • Henan Provincial Department of Science and Technology
  • Health Commission of Henan Province
  • Research Grants Council-CRF Equipment

Zitieren

APA

Wang, C., Chen, J., Li, J., Xu, Z., Huang, L., Zhao, Q., Chen, L., Liang, X., Hu, H., Li, G., Xiong, C., Wu, B., You, H., Du, D., Wang, X., Li, H., Wang, Z., & Chen, L. (2024). An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model. Journal of Clinical Investigation. https://doi.org/10.1172/jci172092

Vancouver

Wang C, Chen J, Li J, Xu Z, Huang L, Zhao Q, et al. An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model. Journal of Clinical Investigation. 2024. doi:10.1172/jci172092

BibTeX
@article{Wang2024,
  author = {Wang, Chenwei and Chen, Jiewen and Li, Jingyao and Xu, Zhihong and Huang, Lihong and Zhao, Qian and Chen, Lei and Liang, Xiaolong and Hu, Hai and Li, Gang and Xiong, Chengjie and Wu, Bin and You, Hua and Du, Danyi and Wang, Xiaoling and Li, Hongle and Wang, Zibing and Chen, Lin},
  title = {An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci172092}
}
Kostenlos starten →